The non-animal testing market enters a phase of major acceleration

According to Allied Market Research, the global non-animal testing market is expected to reach $29.4 billion by 2030, up from $9.8 billion in 2021, representing a compound annual growth rate (CAGR) of 13.5%. This growth is being driven by the convergence of regulatory pressure, biotechnology innovation, and rising ethical expectations from both consumers and industry players.

The sector is undergoing a historic shift following the FDA’s decision to progressively reduce animal testing in pharmaceutical development. Since the FDA Modernization Act 2.0, adopted at the end of 2022, data generated from cell cultures, in silico models, and organ-on-chip systems can officially replace certain animal studies in regulatory submissions. The FDA now aims to make animal testing “the exception rather than the rule” within the next three to five years.

Organ-on-chip technologies are emerging as one of the market’s most strategic segments. These microfluidic devices, designed to replicate the function of human organs, are expected to approach the $1 billion mark by 2030, with annual growth exceeding 34%. Platforms developed by companies such as Emulate and CN Bio already demonstrate greater predictive accuracy for certain drug toxicities than traditional animal models.

Artificial intelligence and in silico approaches are also accelerating the industry’s transformation. Pharmaceutical companies are increasingly relying on computational modeling to predict toxicity, molecular interactions, and ADMET profiles of drug candidates, helping reduce costs and clinical trial failure rates.

The cosmetics industry remains one of the market’s historical growth drivers, supported by European regulations banning animal testing since 2013 and by the global rise of cruelty-free products. Cell-based assays, predictive toxicology, and omics technologies – including genomics, transcriptomics, and proteomics – are seeing strong adoption across the beauty, pharmaceutical, and chemical industries.

North America currently remains the leading market thanks to strong regulatory support from the FDA and NIH, while Asia-Pacific is expected to post the fastest growth, driven by China, South Korea, and India, all of which are investing heavily in biotechnology and animal-free research infrastructure.